Showing 4021-4030 of 6037 results for "".
- TREMFYA (Guselkumab) Improves PsO Symptoms Across All Skin Toneshttps://practicaldermatology.com/news/tremfya-guselkumab-improves-pso-symptoms-across-all-skin-tones/2462086/TREMFYA demonstrated significant skin clearance, rapid scalp psoriasis clearance and improvement in health-related quality of life outcomes in psoriasis patients across all skin tones, according to results from Cohort A of the VISIBLE trial. This study, which was presented at the
- VTAMA (Tapinarof) Cream, 1% Shows Efficacy in Patients With Intertriginous Plaque Psoriasishttps://practicaldermatology.com/news/vtama-tapinarof-cream-1/2462085/VTAMA (tapinarof) Cream, 1% performed well in intertriginous plaque psoriasis (iPsO), according to new Phase 4 data presented at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas. This Phase 4 study expands the body of data for VTAMA cream in adult plaque
- Aquaphor Partners with NBCUniversal and Giselle Blondet for New Campaignhttps://practicaldermatology.com/news/aquaphor-partners-with-nbcuniversal-and-telemundo-personality-giselle-blondet-for-new-campaign/2462084/Aquaphor is partnering with NBCUniversal and Telemundo personality Giselle Blondet to showcase the multiple uses of Aquaphor Baby Healing Ointment across generations. "Aquaphor Baby has been part of our family for many years. What you see is a perfect reflection of my rel
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanomahttps://practicaldermatology.com/news/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma/2462076/IDEAYA Biosciences, Inc. is initiating of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma. There are currently no U.S Food and Drug Administration-approved therapies for this genetically-defined patient population. Darova
- Almost Half of All Skin Disease Patients Report Sleep Issueshttps://practicaldermatology.com/news/almost-half-of-all-skin-disease-patients-report-sleep-issues/2462075/Almost half of all patients with skin disease report sleep disturbances, finds new research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The ALL PROJECT analyzed data on more than 50,000 adults across 20 countries to assess the impact
- Delgocitinib Cream Soothes Moderate to Severe Chronic Hand Eczemahttps://practicaldermatology.com/news/delgocitinib-cream-soothes-moderate-to-severe-chronic-hand-eczema/2462071/Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cream vehicle, according to results from the DELTA 2 trial presented at the European Academy of Derm
- Dermavant’s VTAMA Rapidly Eases Itch in ADhttps://practicaldermatology.com/news/dermavants-vtama-rapidly-eases-itch-in-ad/2462065/Dermavant’s VTAMA (tapinarof) Cream, 1% reduces pruritus in adults and kids with atopic dermatitis as early as 24 hours after the first application, according to new data from ADORING 1 and ADORING 2 presented at the European Academy of Dermatology and Venereology (
- EADV News: Continued Treatment with Opzelura (Ruxolitinib) Cream Shows Efficacy in Nonsegmental Vitiligohttps://practicaldermatology.com/news/eadv-news-continued-treatment-with-opzelura-ruxolitinib-cream-shows-efficacy-in-nonsegmental-vitiligo/2462059/Nonsegmental vitiligo patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura (Ruxolitinib) Cream for up to two years, according to new results of a pooled analysis of long-term ext
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.